ICI in UC: Germany
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

Released: May 13, 2021

Expiration: May 12, 2022

Georgios Gakis
Georgios Gakis, MD

Activity

Progress
1
Course Completed

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:

  • Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
  • Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
  • When to consider first-line treatment with immune checkpoint inhibitor monotherapy
  • Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy

Presenters:

Georgios Gakis, MD  
Professor of Urology, Staff Urologist
University Hospital of Würzburg  
Würzburg, Germany

Mario Wolfgang Kramer, MD, PhD  
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany